BioSpace News Archive

Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced it is presenting a poster at the 2020 American Association of Pharmaceutical Scientists (AAPS) 2020 PharmSci 360 conference, held virtually this year from October 26 – November 5, 2020.

Neogen Corporation (Nasdaq: NEOG) today announced the launch of Igenity® Feeder, a DNA tool designed to assist cattle producers in the stocker and backgrounder phase to rank and manage feeder cattle according to their genetic potential for carcass traits.

Avinger, Inc., a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease, announced that it will release its financial results for the third quarter 2020 after the close of trading on Tuesday, November 10, 2020.

Consumers and businesses require due diligence to ensure they are opting for effective disinfection methods for dangerous viruses and bacteria.

On October 28, 2020, Yuyu Pharm initiated steps to incorporate ISO 37001 Anti-bribery management system to strengthen the company’s compliance system.

Qualigen Therapeutics, Inc. (Nasdaq: QLGN) today announced receipt of written feedback to its Type B Pre-IND (Pre-Investigational New Drug application) meeting request from the U.S. Food and Drug Administration (FDA) that is in general agreement with the Company’s planned clinical development of AS1411

Safeguard Scientifics, Inc. (NYSE:SFE) will release its financial results for the third quarter ended September 30, 2020 prior to market open on Thursday, November 5, 2020.

Perspectum’s new whitepaper clearly outlines how the upfront cost of pre-screening subjects for NASH clinical trial enrollment with non-invasive, MRI-based imaging biomarkers can be significantly offset by the costs saved due to the reduction in total number of biopsies required for trial enrollment.

BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the Company had issued an October 2020 Letter to Shareholders

Dr. King-Kallimanis joins Foundation from position at FDA Oncology Center of Excellence to lead LUNGevity Patient FoRCe research program